Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Cushing Syndrome 6Hypertension 5Diabetes Mellitus, Type 2 5ACTH Syndrome, Ectopic 5Pituitary ACTH Hypersecretion 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Adrenocortical Carcinoma 3Adrenal Cortex Neoplasms 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Processes 1Ovarian Diseases 1Neoplasms by Site 1Hyperglycemia 1Glucose Intolerance 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Endocrine System Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Adrenocortical Hyperfunction 1Adrenal Gland Diseases 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × relacorilant × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05347979 2023-02-09

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Corcept Therapeutics

Phase 1 Completed
30 enrolled

Cushing Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡